Zhimei du

About Zhimei du

18+ years of experience combining extensive business strategy and scientific capabilities across biotherapeutics development areas including cell therapy, gene therapy, stem cell transplantation, monoclonal antibodies, Fc-fusion, Bi/Tri-specific Abs, nanobodies, and peptides. Championed innovation and operational excellence by influencing strategic vision and long-range planning and continually redefining and optimizing organizational structure and capabilities to create a competitive edge for the business. Steered multiple global cross-organizational committee to improve product/process design efficiency through dynamic effort from Research, Discovery, CMC, PKDM, Pre-clinical, Clinical Development, Quality, Supply Chain, and GMP manufacturing. Envisioned and instituted new agile cross-functional drug development roadmap and business strategy from target ID through pivotal clinical trials to accelerate speed to clinic and commercialization. Provided strategic and investment direction in emerging therapeutic areas and modality/platform technologies. Key member of due diligence team for cell/gene therapy pipelines, identifying, evaluating, and negotiating external partnerships that added value to the company. Built various business units/functions from scratch, implementing new facilities infrastructure, state-of-art technologies/platform, and operational/industrial guidelines. Hired, mentored, and managed global multidisciplinary teams of scientists and engineers; contributed to the development of the next generation of leaders and SMEs. Led regulatory filings at the clinical and commercial stages, including IND, BLA/MAA and leveraged in-depth knowledge of FDA, EMA, ICH guidelines, risk management, product changeover, and product/technology transfer processes.

Experience

1. Chief Executive Officer

   Deeptarget Bio

   Jun 2025 — Present

   Led efforts to advance in vivo cell therapy, next-gen T cell engager, and multi-specific immunotherapy, leveraging our proprietary agentic AI platform for groundbreaking novel target discovery, drug design, biomarker, digital twin and clinical development.

Education

• The Rockefeller University

  Postdoctor , Robert G. Roeder Laboratory, Protein Chemistry and Molecular Biology

  2005 — 2008

• Gerstner Sloan Kettering Graduate School of Biomedical Sciences at Memorial Sloan Kettering Cancer Center

  Doctor of Philosophy - PhD, Cancer Immunology

  1998 — 2005

• Beijing Medical University

  Doctor of Medicine - MD

• Saïd Business School, University of Oxford

  Executive Leadership

  2021 — 2021

• University of California, Berkeley

  Venture Capital Scholar - Cohort 20, VC University

  2025 — 2025

• Cornell University

  Ph.D., Immunology

  1998 — 2005

Skills

• Cell
• Drug Discovery
• Elisa
• Project Leadership
• Flow Cytometry
• Expression Vector Engineering
• Antibodies
• Protein Chemistry
• Drug Development
• Monoclonal Antibodies
• Recombinant Protein Expression
• Immunology
• Assay Development
• Molecular Biology
• Vector Engineering
• Molecular Cloning
• Cell Engineering
• Cell Biology
• Protein Purification
• Purification
• Protein Expression
• Cell Culture
• Developing High Throughput and Cell-Based Assay
• High Throughput Screening
• Technology Transfer